In the realm of drug development and safety, NGAL is increasingly recognized as an essential biomarker for evaluating drug-induced kidney injury. During preclinical and clinical trials, monitoring NGAL levels can help identify potential nephrotoxic effects early in the process, thus guiding safer drug design and usage.
